The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Inhaled corticosteroid/long-acting β(2)-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-bl...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Chron Obstruct Pulmon Dis
Huvudupphovsmän: Papi, Alberto, Jones, Paul W, Dalvi, Prashant S, McAulay, Kirsten, McIver, Tammy, Dissanayake, Sanjeeva
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2015
Ämnen:
Methodology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648608/
https://ncbi.nlm.nih.gov/pubmed/26648706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S93375
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk